查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1660555

心臟生物標記的全球市場:市場規模，佔有率，預測，趨勢分析:各類型，各用途，各終端用戶，各地區-2031年為止的預測

Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing ) - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 165 Pages | 訂單完成後即時交付

價格

2023 年心臟生物標記市場規模價值為 51.5 億美元。預計市場規模將從 2024 年的 55.7 億美元成長到 2031 年的 100.8 億美元，2024-2031 年預測期間的複合年增長率為 8.8%。

心臟生物標記市場的成長受到心血管疾病盛行率上升、老年人口增加、心臟生物標記技術進步、醫療保健支出增加以及心血管疾病意識計劃增加的推動。然而，生物標誌物的特異性和敏感性有限以及生物標記測試的高成本限制了該市場的成長。

此外，新型生物標記測試的引入以及生物標記與即時診斷測試的整合有望為市場成長創造機會。然而，替代診斷技術的可用性是全球心臟生物標記市場面臨的主要課題。

依類型劃分，肌鈣蛋白部分在預測期內佔有最大佔有率。該部分佔有率較大可能是由於診斷心血管疾病的高特異性和敏感性、心血管疾病負擔的增加以及推動市場發展的診斷技術的進步。例如，2024 年 10 月，西門子醫療股份公司（德國）的 Atellica IM 高敏肌鈣蛋白 I (TnIH) 測試用於預測心臟病發作的一項新的進步性聲明獲得 FDA 批准。

根據應用，心肌梗塞部分在 2024 年的預測期內佔最大佔有率。這部分的巨大佔有率是由疾病負擔和死亡率的快速增加、對早期診斷認識的不斷提高、即時診斷檢測的進步以及心肌梗塞風險較高且需要心臟生物標誌物的老年人口的快速增加所推動的。

根據最終用戶，預計實驗室測試部分將在 2024 年的預測期內佔據最大佔有率。該部分佔有率較大可歸因於診斷實驗室數量的增加、對疾病早期診斷意識的增強、熟練專業人員的可用性以及對醫療保健基礎設施建設的投資增加。

本報告提供全球心臟生物標記市場相關調查，提供市場現狀，以及各類型，各用途，各終端用戶，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場定義和範圍

第2章 調查手法

第3章 摘要整理

第4章 市場成長的影響因素

  • 概要
  • 促進因素
  • 阻礙因素
  • 機會
  • 課題
  • 趨勢
  • 法規分析
  • 波特的五力分析

第5章 心臟生物標記市場評估，各類型

  • 概要
  • 肌鈣蛋白
  • 肌酸激酶Mb（Ck-Mb）
  • 肌紅蛋白
  • B型利鈉肽（Bnp）
  • N 端前 B 型利鈉肽 (Nt-Probnp)
  • 其他的類型

第6章 心臟生物標記市場評估，各用途

  • 概要
  • 心肌梗塞
  • 急性冠狀動脈症候群
  • 充血性心臟衰竭
  • 其他

第7章 心臟生物標記市場評估，各終端用戶

  • 概要
  • 臨床檢驗
  • 就地檢驗

第8章 心臟生物標記市場評估，各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 瑞士
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 其他
  • 南美
  • 中東·非洲

第9章 競爭分析

  • 概要
  • 主要的成長策略
  • 競爭基準
  • 競爭儀表板
  • 市場佔有率/排行榜分析，各主要企業，2023年

第10章 企業簡介(產業概要，財務概要，產品系列，策略開發，SWOT分析)

  • F. Hoffman-La-Roche Ltd
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineer AG
  • Danaher Corporation
  • bioMerieux SA
  • Becton, Dickinson and Company
  • Life Diagnostics, Inc.
  • Creative Diagnostics
  • Randox Laboratories Ltd
  • QuidelOrtho Corporation

第11章 附錄

Product Code: MRHC - 1041448

Cardiac Biomarkers Market Size, Share, Forecast, & Trends Analysis by Type (Troponin, CK-MB, Myoglobin, BNP), Application (Myocardial Infarction, Congestive Heart Failure), and End User (Laboratory Testing, POC Testing)- Global Forecast to 2031

The cardiac biomarkers market was valued at $5.15 billion in 2023. This market is expected to reach $10.08 billion by 2031 from an estimated $5.57 billion in 2024, at a CAGR of 8.8% during the forecast period of 2024-2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the cardiac biomarkers market is driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, technological advancements in cardiac biomarkers, increasing healthcare expenditure, and increasing cardiovascular disease awareness programs. However, limited specificity and sensitivity of biomarkers and high cost of biomarker testing restrain the growth of this market.

Furthermore, the introduction of novel biomarkers tests and integration of biomarkers in point-of-care testing are expected to generate market growth opportunities. However, the availability of alternative diagnostic technologies are major challenges in the global cardiac biomarkers market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over years (2021-2024). The key players operating in the cardiac biomarkers market are Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), BioMerieux SA (France), Danaher Corporation (U.S.), Creative Diagnostics (U.S.), Life Diagnostics, Inc. (U.S.), Randox Laboratories Ltd. (U.K), Becton, Dickinson and Company (U.S.), and QuidelOrtho Corporation (U.S.).

Among all the type studied in this report, the troponin segment accounted for the largest share during the forecast period. The segment's larger share can be attributed to its high specificity and sensitivity in diagnosing cardiovascular diseases, increasing burden of cardiovascular diseases and advancements in diagnostic technologies drives the market. growing number of product approvals and availability of troponin testing. For instance, in October 2024, Siemens Healthineers AG (Germany) received FDA approval of a new progressive claim for Atellica IM high-sensitivity troponin I (TnIH) test for predicting Heart Attack.

Among all the applications studied in this report, in 2024, myocardial infarction segment accounted for the largest share during the forecast period. The segment's larger share can be attributed to the growing burden of diseases rapidly and mortality rate, increasing awareness about early diagnosis, advancements in point-of-care testing and rapidly growing geriatric population with high risk of myocardial infarction that demands for cardiac biomarkers.

Among all the end user studied in this report, in 2024, laboratory testing segment accounted for the largest share during the forecast period. The segment's larger share can be attributed to the rising number of diagnostics laboratories, increasing awareness about early disease diagnosis, availability of skilled professionals, and increasing investments in developing healthcare infrastructure. laboratory testing can provide high throughput screening capacity for the samples which makes them more efficient for diagnosis procedure.

An in-depth analysis of the geographical scenario of the global cardiac biomarkers market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Asia Pacific is projected to register the highest CAGR during the forecast period. The fastest growth of the market is due to the rising number of cardiovascular diseases, robust healthcare infrastructure, widespread adoption of cardiac biomarkers as a diagnostic and prognostic tool for diseases are further expected to drive the cardiac biomarkers market in the region.

Scope of the Report:

Cardiac biomarkers Market Assessment-by Type

  • Troponin
  • Creatine kinase MB (CK-MB)
  • Myoglobin
  • B-Type Natriuretic Peptide (BNP)
  • N-terminal pro B-type natriuretic peptide (NT-proBNP)
  • Other Types ()

(Note: other types include Galectin, Homocysteine, C-Reactive Protein, and D-dimer)

Cardiac biomarkers Market Assessment-by Application

  • Myocardial Infarction
  • Congestive heart failure
  • Acute Coronary Syndrome
  • Other Applications

(Note: Other applications include Atherosclerosis, Pulmonary Embolism, and Atrial Fibrillation)

Cardiac biomarkers Market Assessment-by End User

  • Laboratory Testing
  • Point-of-care Testing

Cardiac biomarkers Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Spain
    • Switzerland
    • Netherlands
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa

TABLE OF CONTENTS

1. Market Definition & Scope

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
  • 2.3. Market Sizing and Forecast
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions for The Study

3. Executive Summary

4. Factors Affecting Market Growth

  • 4.1. Overview
  • 4.2. Drivers
    • 4.2.1. Increasing Prevalence of Cardiovascular Diseases and Rising Geriatric Population
    • 4.2.2. Technological Advancements in Cardiac Biomarkers
    • 4.2.3. Increasing Healthcare Expenditure
    • 4.2.4. Inreasing Cardiovascular Disease Awareness Programs
  • 4.3. Restraints
    • 4.3.1. Limited Specificity and Sensitivity of Biomarkers
    • 4.3.2. High Cost of Biomarker Testing
  • 4.4. Opportunity
    • 4.4.1. Introduction of Novel Biomarker Tests
    • 4.4.2. Integration of Biomarkers in Point-of-Care Testing
  • 4.5. Challenges
    • 4.5.1. Alternative Diagnostic Technologies
  • 4.6. Trends
    • 4.6.1. Focus on Multi-Analyte Panels
  • 4.7. Regulatory Analysis
  • 4.8. Porter's Five Forces Analysis

5. Cardiac Biomarkers Market Assessment-By Type

  • 5.1. Overview
  • 5.2. Troponin
  • 5.3. Creatine Kinase Mb (Ck-Mb)
  • 5.4. Myoglobin
  • 5.5. B-Type Natriuretic Peptide (Bnp)
  • 5.6. N-Terminal Pro-B-Type Natriuretic Peptide (Nt-Probnp)
  • 5.7. Other Types

6. Cardiac Biomarkers Market Assessment-By Application

  • 6.1. Overview
  • 6.2. Myocardial Infarction
  • 6.3. Acute Coronary Syndrome
  • 6.4. Congestive Heart Failure
  • 6.5. Other Applications

7. Cardiac Biomarkers Market Assessment-By End User

  • 7.1. Overview
  • 7.2. Laboratory Testing
  • 7.3. Point-of-Care Testing

8. Cardiac Biomarkers Market Assessment-By Geography

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. France
    • 8.3.3. Uk
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Switzerland
    • 8.3.7. Rest of Europe (Roe)
  • 8.4. Asia-Pacific
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Rest of Asia-Pacific (Roapac)
  • 8.5. Latin America
  • 8.6. Middle East & Africa

9. Competition Analysis

  • 9.1. Overview
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Benchmarking
  • 9.4. Competitive Dashboard
    • 9.4.1. Industry Leaders
    • 9.4.2. Market Differentiators
    • 9.4.3. Vanguards
    • 9.4.4. Emerging Companies
  • 9.5. Market Share/Ranking Analysis, By Key Players, 2023

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and Swot Analysis*)

  • 10.1. F. Hoffman-La-Roche Ltd (Switzerland)
  • 10.2. Bio-Rad Laboratories, Inc. (U.S.)
  • 10.3. Abbott Laboratories (U.S.)
  • 10.4. Thermo Fisher Scientific Inc. (U.S.)
  • 10.5. Siemens Healthineer AG (Germany)
  • 10.6. Danaher Corporation (U.S.)
  • 10.7. bioMerieux SA (France)
  • 10.8. Becton, Dickinson and Company (U.S.)
  • 10.9. Life Diagnostics, Inc. (U.S.)
  • 10.10. Creative Diagnostics (U.S.)
  • 10.11. Randox Laboratories Ltd (U.K.)
  • 10.12. QuidelOrtho Corporation (U.S.)

(Note: Swot Analysis* Will Be Provided of The Top 5 Companies)

11. Appendix

  • 11.1. Available Customization
  • 11.2. Related Reports

LIST OF TABLES

  • Table 1. Key Government Regulatory Agencies
  • Table 2. Cardiac Biomarker Types: Advantages & Disadvantages
  • Table 3. Global Cardiac Biomarkers Market Size, By Type, 2022-2031 (USD Million)
  • Table 4. Global Troponin Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 5. Global Creatine Kinase Mb (Ck-Mb) Biomarkers Market, By Country/ Region, 2022-2031 (USD Million)
  • Table 6. Global Myoglobin Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 7. Global BNP Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 8. Difference Between BNP and NT-proBNP
  • Table 9. Global NT-proBNP Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 10. Global Other Biomarker Types Market, By Country/Region, 2022-2031 (USD Million)
  • Table 11. Global Cardiac Biomarkers Market Size, By Application, 2022-2031 (USD Million)
  • Table 12. Global Cardiac Biomarkers Market for Myocardial Infarction, By Country/Region, 2022-2031 (USD Million)
  • Table 13. Global Cardiac Biomarkers Market for Acute Coronary Syndrome, By Country/Region, 2022-2031 (USD Million)
  • Table 14. Global Cardiac Biomarkers Market for Congestive Heart Failure, By Country/Region, 2022-2031 (USD Million)
  • Table 15. Global Cardiac Biomarkers Market for Other Application, By Country/Region, 2022-2031 (USD Million)
  • Table 16. Global Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 17. Global Cardiac Biomarkers Market for Laboratory Testing, By Country/Region, 2021-2031 (USD Million)
  • Table 18. Global Cardiac Biomarkers Market for Point-of-Care Testing, By Country/Region, 2021-2031 (USD Million)
  • Table 19. Global Cardiac Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 20. North America: Cardiac Biomarkers Market, By Country, 2022-2031 (USD Million)
  • Table 21. North America: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 22. North America: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 23. North America: Cardiac Biomarkers Market, By End Use, 2022-2031 (USD Million)
  • Table 24. U.S.: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 25. U.S.: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 26. U.S.: Cardiac Biomarkers Market, By End Use, 2022-2031 (USD Million)
  • Table 27. Canada: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 28. Canada: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 29. Canada: Cardiac Biomarkers Market, By End Use, 2022-2031 (USD Million)
  • Table 30. Europe: Cardiac Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 31. Europe: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 32. Europe: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 33. Europe: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 34. Germany: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 35. Germany: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 36. Germany: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 37. France: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 38. France: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 39. France: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 40. U.K.: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 41. U.K.: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 42. U.K.: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 43. Italy: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 44. Italy: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 45. Italy: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 46. Spain: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 47. Spain: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 48. Spain: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 49. Switzerland: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 50. Switzerland: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million
  • Table 51. Switzerland: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 52. Rest of Europe: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 53. Rest of Europe: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 54. Rest of Europe: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 55. Asia-Pacific: Cardiac Biomarkers Market, By Country/Region, 2022-2031 (USD Million)
  • Table 56. Asia-Pacific: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 57. Asia-Pacific: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 58. Asia-Pacific: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 59. Japan: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 60. Japan: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 61. Japan: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 62. China: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 63. China: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 64. China: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 65. India: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 66. India: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 67. India: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 68. Australia: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 69. Australia: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 70. Australia: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 71. Rest of Asia Pacific: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 72. Rest of Asia Pacific: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 73. Rest of Asia Pacific: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 74. Latin America: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 75. Latin America: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 76. Latin America: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 77. Middle East & Africa: Cardiac Biomarkers Market, By Type, 2022-2031 (USD Million)
  • Table 78. Middle East & Africa: Cardiac Biomarkers Market, By Application, 2022-2031 (USD Million)
  • Table 79. Middle East & Africa: Cardiac Biomarkers Market, By End User, 2022-2031 (USD Million)
  • Table 80. Recent Developments, By Company, 2021-2024

LIST OF FIGURES

  • Figure 1. Market Ecosystem
  • Figure 2. Secondary Sources referenced for this study
  • Figure 3. Primary Research Techniques
  • Figure 4. Key Executives Interviewed
  • Figure 5. Breakdown of Primary Interviews (Supply Side & Demand Side)
  • Figure 6. Market Sizing & Growth Forecast Approach
  • Figure 7. Global Cardiac biomarkers Market, By Type, 2024 VS. 2031 (USD Million)
  • Figure 8. Global Cardiac biomarkers Market, By Application, 2024 VS. 2031 (USD Million)
  • Figure 9. Global Cardiac biomarkers Market, By End User, 2024 VS. 2031 (USD Million)
  • Figure 10. Global Cardiac biomarkers Market, By Geography, 2024 VS. 2031 (USD Million)
  • Figure 11. Impact Analysis of Market Dynamics
  • Figure 12. USFDA regulatory pathways for cardiac biomarkers
  • Figure 13. EU regulatry pathway - IVDR 2017/746
  • Figure 14. China: medical device classification and premarket requirements for crdaiac biomarkers products
  • Figure 15. Porter's Five Forces Analysis: cardiac biomarkers market
  • Figure 16. Global Cardiac biomarkers Market, By Type, 2024 VS. 2031 (USD Million)
  • Figure 17. Global Cardiac biomarkers Market, By Application, 2024 VS. 2031 (USD Million)
  • Figure 18. Global Cardiac biomarkers Market, By End User, 2024 VS. 2031 (USD Million)
  • Figure 19. Global pharmaceutical R&D spending, 2012-2026 (USD Billion)
  • Figure 20. Global Cardiac biomarkers Market, By Geography, 2024 VS. 2031 (USD Million)
  • Figure 21. North America: Cardiac biomarkers Market Snapshot
  • Figure 22. U.S. population aged 65 years and above, 2022-2026 (million)
  • Figure 23. U.S.: cardiovascular diseases prevalence rate in the population, 2021-2035
  • Figure 24. Europe: Cardiac biomarkers Market Snapshot
  • Figure 25. Asia Pacific: Cardiac biomarkers Market Snapshot
  • Figure 26. Latin America: Cardiac biomarkers Market Snapshot
  • Figure 27. Middle East & Africa: Cardiac biomarkers Market Snapshot
  • Figure 28. Key Growth Strategies Adopted By Leading Players, 2021-2024
  • Figure 29. Cardiac biomarkers Market: Competitive Benchmarking, By Type
  • Figure 30. Cardiac biomarkers Market: Competitive Benchmarking, By Region
  • Figure 31. Cardiac biomarkers Market: Competitive Dashboard
  • Figure 32. Cardiac biomarkers Market: Market Share Analysis, By Key Players (2023)
  • Figure 33. F. Hoffman-La-Roche Ltd: Financial Snapshot (2023)
  • Figure 34. Bio-Rad Laboratories, Inc.: Financial SNAPSHOT (2023)
  • Figure 35. Abbott Laboratories: Financial Snapshot (2023)
  • Figure 36. Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
  • Figure 37. Siemens Healthineer AG: Financial Snapshot (2024)
  • Figure 38. Danaher Corporation: Financial Snapshot (2023)
  • Figure 39. bioMerieux SA: Financial Snapshot (2023)

FIGURE 40. Becton, Dickinson and Company: FINANCIAL SNAPSHOT (2024)

  • Figure 41. QuidelOrtho Corporation: FINANCIAL SNAPSHOT (2023)